A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
Completed
Ionis Pharmaceuticals, Inc.
Phase 2
1969-12-31
To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an
additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV)
retinitis.
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
Completed
Ionis Pharmaceuticals, Inc.
N/A
1969-12-31
The purpose of this study is to compare the safety and effectiveness of two dosage schedules
for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
Completed
Ionis Pharmaceuticals, Inc.
N/A
1969-12-31
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to
compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with
previously untreated, peripheral cytomegalovirus ( CMV ) retinitis.
The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
Completed
Ionis Pharmaceuticals, Inc.
Phase 2
1969-12-31
To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV
) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are
otherwise ineligible for ISIS Pharmaceuticals' controlled trials OR who have failed ISIS 2922
therapy on another controlled clinical trial.
PER 2/8/96 AMENDMENT: Patients must rollover from another ISIS 2922 controlled trial.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
